Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; indigo carmine; iron oxide yellow; iron oxide red; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 3 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; indigo carmine; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; erythrosine; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - warfarin sodium 1mg - tablet - 1 mg - active: warfarin sodium 1mg excipient: indigo carmine iron oxide red iron oxide yellow lactose monohydrate magnesium stearate maize starch pregelatinised maize starch sodium starch glycolate - coronary occlusion; deep vein thrombosis; pulmonary embolism; peripheral vascular thromboembolic states.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - warfarin sodium 3mg - tablet - 3 mg - active: warfarin sodium 3mg excipient: indigo carmine lactose monohydrate magnesium stearate maize starch pregelatinised maize starch sodium starch glycolate - coronary occlusion; deep vein thrombosis; pulmonary embolism; peripheral vascular thromboembolic states.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - warfarin sodium 5mg - tablet - 5 mg - active: warfarin sodium 5mg excipient: erythrosine lactose monohydrate magnesium stearate maize starch pregelatinised maize starch sodium starch glycolate - coronary occlusion; deep vein thrombosis; pulmonary embolism; peripheral vascular thromboembolic states.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - warfarin sodium - tablet - 3 mg - warfarin sodium 3 mg

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - warfarin sodium - tablet - 5 mg - warfarin sodium 5 mg

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - warfarin sodium - tablet - 1 mg - warfarin sodium 1 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; povidone; hypromellose - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.